BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21967115)

  • 1. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg.
    Damian DL; Thompson JF
    Am J Clin Dermatol; 2011 Dec; 12(6):403-4. PubMed ID: 21967115
    [No Abstract]   [Full Text] [Related]  

  • 2. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
    Damian DL; Saw RP; Thompson JF
    J Surg Oncol; 2014 Mar; 109(4):308-13. PubMed ID: 24522938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma.
    Damian DL; Shannon KF; Saw RP; Thompson JF
    Australas J Dermatol; 2009 Nov; 50(4):266-71. PubMed ID: 19916970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience.
    Gibbons IL; Sonagli M; Bertolli E; Macedo MP; Pinto CAL; Duprat Neto JP
    An Bras Dermatol; 2018 Mar; 93(2):299-301. PubMed ID: 29723355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response rates of cutaneous melanoma metastases to diphencyprone: A meta-analysis.
    Lôbo MM; Calsavara VF; Ricci BV; Lopes Pinto CA; Bertolli E; Duprat Neto JP
    J Am Acad Dermatol; 2020 Dec; 83(6):1812-1813. PubMed ID: 32289400
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone.
    Damian DL; Thompson JF
    J Am Acad Dermatol; 2007 May; 56(5):869-71. PubMed ID: 17276544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin; the 5-year Norwich experience.
    Moncrieff M; Fadhil M; Garioch J
    Br J Dermatol; 2016 May; 174(5):1141-2. PubMed ID: 26598951
    [No Abstract]   [Full Text] [Related]  

  • 8. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
    Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
    Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
    [No Abstract]   [Full Text] [Related]  

  • 9. Complete remission of extensive cutaneous metastatic melanoma on the scalp under topical mono-immunotherapy with diphenylcyclopropenone.
    Hinz T; Ehler LK; Bieber T; Schmid-Wendtner MH
    Eur J Dermatol; 2013; 23(4):532-3. PubMed ID: 24002471
    [No Abstract]   [Full Text] [Related]  

  • 10. Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
    Yeung C; Petrella TM; Wright FC; Abadir W; Look Hong NJ
    Expert Rev Clin Immunol; 2017 Apr; 13(4):383-388. PubMed ID: 28121191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma.
    Trefzer U; Sterry W
    Dermatology; 2005; 211(4):370-1. PubMed ID: 16286751
    [No Abstract]   [Full Text] [Related]  

  • 12. Congenital malignant melanoma and cutaneous metastases treated with diphencyprone.
    Fawcett JM; Newell EL; Kennedy CT
    Clin Exp Dermatol; 2016 Mar; 41(2):212-3. PubMed ID: 26053880
    [No Abstract]   [Full Text] [Related]  

  • 13. Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine.
    Harland CC; Saihan EM
    Lancet; 1989 Aug; 2(8660):445. PubMed ID: 2569622
    [No Abstract]   [Full Text] [Related]  

  • 14. Dramatic regression of cutaneous, nodal, and visceral melanoma metastases.
    Damian DL; Saw RPM
    J Am Acad Dermatol; 2011 Sep; 65(3):665-666. PubMed ID: 21839330
    [No Abstract]   [Full Text] [Related]  

  • 15. Dual fronts poised to transform melanoma therapy.
    Mullard A
    Nat Rev Drug Discov; 2011 May; 10(5):325-6. PubMed ID: 21532549
    [No Abstract]   [Full Text] [Related]  

  • 16. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone.
    Martiniuk F; Damian DL; Thompson JF; Scolyer RA; Tchou-Wong KM; Levis WR
    J Drugs Dermatol; 2010 Nov; 9(11):1368-72. PubMed ID: 21061759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience.
    Veverka KK; Jakub JW; Baum CL
    Dermatol Surg; 2018 Dec; 44(12):1501-1508. PubMed ID: 29985863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis.
    Pham JP; Dwyer L; Phan K; Menzies AM; Frew JW
    Melanoma Res; 2023 Oct; 33(5):434-436. PubMed ID: 37650727
    [No Abstract]   [Full Text] [Related]  

  • 19. PD-L1 expression as a potential predictive biomarker.
    Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
    Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
    [No Abstract]   [Full Text] [Related]  

  • 20. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.